09.24.24 -- The Latest Trends In The Prevention And Treatment Of Cervical Cancer

What immune checkpoint inhibitors are showing promise in cervical cancer treatments and how are advancements in treatment, paired with additional prevention strategies, improving patient outcomes?

Delve into the fundamental elements necessary for establishing trust and efficiency in client-CDMO collaborations and learn how to navigate the complex landscape of CDMO partnerships.

Market dynamics will continue to favor engaging with CDMO partners who have the capabilities and experience to manage short-term needs while anticipating and planning for long-term requirements.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

Industry experts answer attendee questions from a recent webinar about sustainability concerns surrounding oligonucleotide manufacturing.

Partnering with a CDMO can offer numerous benefits, however, several challenges must also be navigated. Review key considerations for overcoming these challenges and enhancing collaboration.

The design of bispecific antibodies requires a comprehensive assessment that takes into account: half-life, mechanism of action, and manufacturing challenges like impurities and low yield.

Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success.

Learn how a CDMO can form strong partnerships by promoting innovation as well as respecting the unique manufacturing needs of early-stage companies and small-scale programs.

Determining ideal media composition for a bacteria is critical because it fosters a satisfactory grow rate, allowing the bacteria to reach the required growth yield.

Discover the strategies that helped a company navigate a complex and shifting regulatory landscape to rapidly re-engineer a COVID-19 vaccine manufacturing process for FDA compliance.

Understanding the obstacles you may face during bioconjugate development, as well as the tools available to help overcome them, can help streamline your product’s path to market.

Review the benefits of a co-transcriptional capping RNA polymerase engineered to produce synthetic RNA to meet these increasing demands for safety and cost-effectiveness.

Leveraging the experience and specialized technology of a reliable CDMO partner is essential to ensure your sterile injectable therapeutic's safety and quality while delivering at speed.

Explore flexible platform technologies that drive next-gen bioprocessing efficiencies and advanced analytics that enhance product characterization and support regulatory requirements.

Learn how to navigate decision-making at critical steps and find solutions to key challenges in process development and scale-up to expedite oncolytic virus programs.

Explore a HEK293 derived animal component-free suspension cell line as the foundation of an up to 2000-liters scalable and robust platform process that increases the speed of AAV manufacturing.